LIXTE Biotechnology Advances NOMAD Acquisition with $6.5 Million Pre-Closing Loan

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced that its previously disclosed acquisition of NOMAD Transportable Power Systems is expected to close on or about July 1, 2026, subject to customary conditions and approvals. Ahead of closing, LIXTE will provide a $6.5 million loan to NOMAD to support procurement of long-lead components, fund working capital and help the company scale manufacturing against its growing order pipeline for deployable utility-grade battery energy storage systems.

Upon completion of the transaction, the company expects to rename itself NOMAD Power Solutions, Inc. and adopt a new Nasdaq ticker symbol. NOMAD’s mobile, utility-grade battery energy storage platform is designed to provide rapid deployment and reliable power for utilities, industrial users and data centers, positioning the company to benefit from rising electricity demand driven by artificial intelligence infrastructure and high-density computing applications.

For more details, the full press release is available at https://ibn.fm/s0uCh.

LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical and med-tech company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that LB-100, its lead compound and first-in-class lead clinical PP2A inhibitor, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. It is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE’s novel approach is covered by a comprehensive patent portfolio, with proof-of-concept clinical trials currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.

Through LIXTE’s wholly owned subsidiary, Liora Technologies Europe Ltd., the Company also is pioneering the development of electronically controlled proton therapy systems for treating tumors in various types of cancers. Liora’s proprietary flagship technology, LiGHT System, is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy. Additional information about Liora Technologies can be found at www.lioratechnologies.com.

This acquisition marks a strategic shift for LIXTE, diversifying from its core cancer-focused operations into the energy storage sector. The loan underscores LIXTE's commitment to NOMAD's growth and the potential for the combined entity to address critical energy infrastructure needs. With the expected closing in 2026, investors and industry observers will be watching for regulatory approvals and the integration of NOMAD's technology into LIXTE's portfolio.